Abstract | OBJECTIVES: METHODS: Rats were divided into three groups: control (C), rolipram (R) and sham (S). In the C and R groups, animals underwent CPB at a flow rate of 60 ml/kg per min for 60 min followed by another 60-min observation, whereas the S group rats were sustained for 120 min only with median sternotomy and the placement of cannulae for CPB. Rolipram (40 microg/kg per min) was administered to the R group rats by continuous intravenous infusion from 10 min before the establishment of CPB to the end of the experiment. RESULTS: The R and S groups showed significantly higher mean arterial oxygen pressure and lower mean lung wet-to-dry weight ratio compared with those observed in the C group (R: 489+/-44 or S: 527+/-55 vs. C: 287+/-185, and R: 5.0+/-0.4 or S: 4.7+/-0.3 vs. C: 5.9+/-0.5, respectively; (P < 0.01). Although CD11b expression levels on circulating neutrophils in the C group doubled after CPB, those in the R and S groups remained almost the same (P = 0.0008). Intrapulmonary tumor necrosis factor-alpha concentrations (pg/microg protein) in the C group tended to be higher than those observed in the R and S groups (R: 5.2+/-2.1, S: 5.0+/-2.1 and C: 8.9+/-5.4; R vs. C: P = 0.09 and S vs. C: P = 0.08). Pathological study of lungs revealed that more alveolar hemorrhage and neutrophil accumulation were observed in the C group compared to the R and S groups. CONCLUSIONS: These results suggest that rolipram prevents acute lung injury via the inhibition of neutrophil activation during and after CPB in this setting of a rat model.
|
Authors | Masaki Hamamoto, Michiharu Suga, Takeshi Nakatani, Yuzo Takahashi, Yukio Sato, Shuji Inamori, Toshikatsu Yagihara, Soichiro Kitamura |
Journal | European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
(Eur J Cardiothorac Surg)
Vol. 25
Issue 5
Pg. 833-8
(May 2004)
ISSN: 1010-7940 [Print] Germany |
PMID | 15082290
(Publication Type: Journal Article)
|
Chemical References |
- CD11b Antigen
- Phosphodiesterase Inhibitors
- Tumor Necrosis Factor-alpha
- L-Selectin
- 3',5'-Cyclic-AMP Phosphodiesterases
- Cyclic Nucleotide Phosphodiesterases, Type 4
- Rolipram
|
Topics |
- 3',5'-Cyclic-AMP Phosphodiesterases
(antagonists & inhibitors)
- Animals
- CD11b Antigen
(blood)
- Cardiopulmonary Bypass
(adverse effects)
- Cyclic Nucleotide Phosphodiesterases, Type 4
- Disease Models, Animal
- L-Selectin
(blood)
- Male
- Neutrophil Activation
(drug effects)
- Phosphodiesterase Inhibitors
(therapeutic use)
- Rats
- Rats, Sprague-Dawley
- Respiratory Distress Syndrome
(etiology, pathology, prevention & control)
- Rolipram
(therapeutic use)
- Tumor Necrosis Factor-alpha
(metabolism)
|